Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome

Neuropharm

Status and phase

Completed

Phase 2

Phase 1

Conditions

Fragile X Syndrome

Treatments

Drug: NPL-2009

Study type

Interventional

Funder types

Industry

Identifiers

NCT00637221

NPL-2009-2-FEN-001

Details and patient eligibility

About

This is an open label exploratory study to investigate the safety and effects of a single dose of NPL-2009(50 mg - 150 mg) on Prepulse Inhibition (PPI) Tests and Continuous Performance Tasks (CPT) in adults with Fragile X Syndrome

Enrollment

12 patients

Sex

All

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female patients, 18 to 45 years of age.
Diagnosis of Fragile X Syndrome.
Females must demonstrate a negative pregnancy test at screening.
Females of child-bearing potential must be using a medically accepted means of contraception or must remain abstinent for the duration of the study.
Each Legally Authorised Representative (LAR, usually parent or caregiver) must have a level of understanding sufficient to provide written informed consent to all required study tests and procedures.
Each patient must consent/assent (depending on center-specific procedures) to all required study tests and procedures.
Permitted concomitant medications must be stable for at least 6 weeks prior to enrollment. The following concomitant medications are permitted: psychostimulants, SSRIs, atypical antipsychotics, anticonvulsants which do not have liver inducing effects, clonidine.
Each patient must be able to swallow the capsules (2, 3 or 4) to be provided in the study.

Exclusion criteria

Current treatment with anticonvulsants known to induce liver enzymes e.g. depakote
Current treatment with N-methyl-D-aspartate (NMDA) antagonists
Current treatment with tricyclic antidepressants
Current treatment with typical antipsychotics
Current treatment with lithium
Patients planning to commence cognitive behaviour therapy during the period of the study or those who have begun cognitive behavioural therapy within 6 weeks prior to enrolment.
History of, or current cardiovascular, renal, hepatic, respiratory and particularly gastrointestinal disease which may interfere with the absorption, distribution, metabolism or excretion of the study medication.
History of, or current cerebrovascular disease or brain trauma.
History of, or current significant endocrine disorder, e.g. hypo or hyperthyroidism.
History of, or current malignancy.
Presence of psychotic symptoms or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder, as assessed by the Investigator.
Current major depressive disorder (patients must be free of the disorder for 3 months prior to enrolment).
Judged clinically to be at risk of suicide (suicidal ideation, severe depression, or other factors), as assessed by the Investigator.
Tourette's Disorder.
Female patients who are either pregnant or nursing.
Current drug abuse or dependence disorder or dependency in the 3 months prior to enrolment.
Clinically significant abnormalities in safety laboratory tests, vital signs or EKG, as measured at screening
Patients with significant hearing and/or visual impairments that may affect their ability to complete the test procedures
Enrollment in another clinical trial within the previous 30 days